Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
Swiss Mountaineer Dani Arnold breaks the record for the quickest ascent of the north face of the Matterhorn mountain in the Alps. The 1,100 meter-high climb usually takes mountain climbers between ...
Victory Ventures, in collaboration with Matterhorn Venture Partners, proudly announces the acquisition of a 22,500 ...
The Matterhorn is surely the world’s most iconic peak. Its commanding, isolated position at the head of the valley is unique in the Alps and its claim to being one of the world’s most beautiful ...
Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback